ERBB2 and neoplasm: An early Phase I study evaluating [89Zr]Zr-trastuzumab for PET imaging in 12 female HER2+ BCa patients (six of which had primary and six had metastatic BCa) showed an excellent tumor delineation of tumor lesions and no adverse effects.